BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
40
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PADCEV (enfortumab vedotin) is an antibody-drug conjugate (ADC) that targets Nectin-4, a tumor-associated antigen expressed on urothelial carcinoma and other solid tumors. It delivers a microtubule-disrupting payload (monomethyl auristatin E) directly to cancer cells expressing Nectin-4. PADCEV is indicated across a broad spectrum of Nectin-4-positive cancers including urothelial carcinoma, salivary gland carcinoma, adenoid cystic carcinoma, and multiple other solid tumors.
$4MPart D
PeakPADCEV is at peak commercial stage with modest Part D spend, indicating established market presence but room for expansion; team size likely stable with focus on indication expansion and market penetration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (40)
Study of EV for Recurrent Endometrial Carcinoma
Started Apr 2026
12 enrolled
Endometrial Cancer
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Started Apr 2026
37 enrolled
Advanced Urothelial CancerMetastatic Urothelial Carcinoma
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Started Mar 2026
240 enrolled
Muscle-invasive Bladder Cancer
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Started Mar 2026
132 enrolled
Urothelial CancerAdvanced/Metastatic Urothelial CancerUrothelial Carcinoma
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Started Feb 2026
0Metastatic Urothelial CarcinomaUrothelial CarcinomaLocally Advanced Urothelial Carcinoma+1 more
Worked on PADCEV at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.